- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Joseph Fuhr: The Immediate Economic Impact of Biosimilars May be Limited
Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, sees a limited economic impact for biosimilars given current patent disputes.
Transcript (slightly modified)
What will be the immediate economic impact of biosimilars?
In the next few years I see very little economic impact (of biosimilars). There are currently 2 in the market and they are both risk launches. All are involved in various patent disputes and the Supreme Court is looking at 2 issues concerning the 180-day notice of entry and the other concerning whether the patent dance is mandatory.
As with any new industry, [biosimilars] will take time to develop and so their economic impact will be minimal.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
